On February 16, 2022 Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, reported that it will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the U.S. financial markets close (Press release, Dynavax Technologies, FEB 16, 2022, View Source [SID1234608185]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dynavax will host a conference call and live audio webcast on Monday, February 28, 2022 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company’s website at View Source Alternatively, participants may dial (866) 420-4066 or (409) 217-8237 and refer to conference ID 4678925. A replay of the webcast will be available for 30 days following the live event.

On February 16, 2022 Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, reported that it will provide a corporate update and report financial results for the fourth quarter and full year 2021 after the market closes on Wednesday, February 23, 2022 (Press release, Xencor, FEB 16, 2022, View Source [SID1234608184]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Xencor management will host a conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to provide a corporate update.

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers and referencing conference ID number 5290676. A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com. The webcast will be archived on the company website for 30 days.

On February 16, 2022 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that management will participate in two upcoming virtual conferences (Press release, BioMarin, FEB 16, 2022, View Source [SID1234608183]). An audio webcast of the presentations will be available live. You can access the webcast at: View Source An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 16, 2022 Amgen (NASDAQ:AMGN) reported that it has been named to Newsweek magazine’s list of "America’s Most Responsible Companies" for the third consecutive year; JUST Capital’s list of "America’s Most JUST Companies" for the fifth consecutive year; Barron’s list of "America’s Most Sustainable Companies" for the second consecutive year; and the Human Rights Campaign Foundation’s list of "Best Places to Work for LGBTQ+ Equality" for the sixth consecutive year (Press release, Amgen, FEB 16, 2022, View Source [SID1234608182]). These rankings reflect the company’s enduring commitment to environmental, social, and governance (ESG) issues.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Amgen’s mission is to serve patients and our ESG programs enable us to achieve that mission responsibly," said Judy Brown, senior vice president, Corporate Affairs at Amgen. "We will continue to do our part to build a better, healthier world by addressing the challenges facing society that matter most to our business and to our stakeholders."

Amgen’s four ESG pillars – Healthy People, Healthy Society, Healthy Planet, and a Healthy Amgen – include commitments to:

Achieve carbon neutrality by 2027, along with a 40% reduction in water used and a 75% reduction in waste disposed.1
Improve the diversity of its workforce as well as the diversity of patients participating in clinical trials of potential new Amgen medicines.
Provide employees with enhanced mental health support, including programs focused on communities of color, as well on the pandemic-related challenges facing parents.
Double its spend with diverse suppliers in the U.S. and triple its spend with Black-owned businesses by 2023.
Inspire the next generation of innovators through science education programs sponsored by the Amgen Foundation2 that reached over 24 million students worldwide last year.
Help those who are unable to afford the medicines they need through the Amgen Safety Net Foundation3, which has provided approximately $6 billion4 of our medicines at no cost over the past five years to qualifying patients in the United States.

On February 16, 2022 BioCanRx reported Dr. Carl H. June as our distinguished keynote speaker for the 2022 Summit for Cancer Immunotherapy (Summit4CI) taking place November 19-21, 2022 (Press release, BioCanRx, FEB 16, 2022, View Source;utm_medium=rss&utm_campaign=carl-h-june-keynote-speaker-2021-summit4ci-2 [SID1234608181]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. June is the Richard W. Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania. The impact of his work has become widely recognized as a major turning point that is delivering on the long-held promise of cancer gene therapy. Dr. June is a pioneer in immunotherapy research who spearheaded the development of chimeric antigen receptor (CAR) T-cell therapy, a new tool for treating cancer that involves extracting a patient’s immune cells and genetically engineering them so they can attack and kill their cancer. This treatment received FDA approval in August 2017, followed by more approvals for varying countries and indications. Dr. June has published over 350 manuscripts and has received multiple awards and honours.

Summit4CI 2022 is taking place in Montréal, Quebec, at the Fairmont the Queen Elizabeth. Please join us Saturday, November 19 to Monday, November 21 as we explore the latest progress in cancer immunotherapy from scientific, clinical, industry and patient perspectives during BioCanRx’s sixth scientific conference. In addition to our feature keynote speaker Dr. June, this year’s Summit4CI will feature internationally recognized speakers, networking and social events, an HQP Development Day, scientific presentations, poster sessions, a public forum, an Oxford-style debate, and more. We hope to see you at the conference! Learn more here.